These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2694814)

  • 1. The immunobiology of respiratory syncytial virus: prospects for a vaccine.
    Norrby E; Akerlind B; Mufson MA
    Adv Exp Med Biol; 1989; 257():147-53. PubMed ID: 2694814
    [No Abstract]   [Full Text] [Related]  

  • 2. [Respiratory syncytial virus and immune response: from the diagnosis of infection to prospects of vaccination].
    Pothier P
    Pediatrie; 1991; 46(8-9 Suppl):1-4. PubMed ID: 1665219
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogen-induced enhanced pulmonary histopathology in the RSV cotton rat model.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):689-90. PubMed ID: 8322496
    [No Abstract]   [Full Text] [Related]  

  • 4. Approaches to immunization against respiratory syncytial virus.
    Wertz GW; Sullender WM
    Biotechnology; 1992; 20():151-76. PubMed ID: 1600380
    [No Abstract]   [Full Text] [Related]  

  • 5. The envelope proteins from purified respiratory syncytial virus protect mice from intranasal virus challenge.
    Levine S; Dillman TR; Montgomery PC
    Proc Soc Exp Biol Med; 1989 Apr; 190(4):349-56. PubMed ID: 2928348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.
    Trudel M; Nadon F; Séguin C; Binz H
    Virology; 1991 Dec; 185(2):749-57. PubMed ID: 1720589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The status of research to develop new vaccines against infection caused by the respiratory syncytial virus].
    Pervikov IuV; Litvinov SK
    Vopr Virusol; 1988; 33(5):523-9. PubMed ID: 3064426
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
    Hsu KH; Lubeck MD; Davis AR; Bhat RA; Selling BH; Bhat BM; Mizutani S; Murphy BR; Collins PL; Chanock RM
    J Infect Dis; 1992 Oct; 166(4):769-75. PubMed ID: 1527411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.
    Vaux-Peretz F; Chapsal JM; Meignier B
    Vaccine; 1992; 10(2):113-8. PubMed ID: 1539464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
    Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein.
    Melero JA; García-Barreno B; Martínez I; Pringle CR; Cane PA
    J Gen Virol; 1997 Oct; 78 ( Pt 10)():2411-8. PubMed ID: 9349459
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prospects of respiratory syncytial virus vaccines].
    Tarro G
    Ann Sclavo; 1980; 22(1):40-1. PubMed ID: 7247482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.
    Openshaw PJ; Anderson K; Wertz GW; Askonas BA
    J Virol; 1990 Apr; 64(4):1683-9. PubMed ID: 2319650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):615-8. PubMed ID: 8322482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector.
    Wathen MW; Brideau RJ; Thomsen DR
    J Infect Dis; 1989 Feb; 159(2):255-64. PubMed ID: 2644369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.
    Taylor G; Stott EJ; Furze J; Ford J; Sopp P
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2217-23. PubMed ID: 1383403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary pulmonary murine cytotoxic T lymphocyte specificity in respiratory syncytial virus pneumonia.
    Gupta R; Yewdell JW; Olmsted RA; Collins PL; Bennink JR
    Microb Pathog; 1990 Jul; 9(1):13-8. PubMed ID: 2077342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice.
    Brideau RJ; Wathen MW
    Vaccine; 1991 Dec; 9(12):863-4. PubMed ID: 1811371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
    Arbiza J; Taylor G; López JA; Furze J; Wyld S; Whyte P; Stott EJ; Wertz G; Sullender W; Trudel M
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2225-34. PubMed ID: 1383404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.